Aion Therapeutic Inc will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: Benzinga Cannabis Capital ConferenceBenzinga’s …
Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https:events.benzinga.comccc-free-registration.
About Benzinga Cannabis Capital Conference
Benzinga’s virtual Cannabis Capital Conference is guaranteed to offer participants all the benefits of an immersive and robust in-person conference from any remote location. The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space. Don’t miss this opportunity to connect with THE cannabis movers and shakers from across the globe.
For more information and/or to register for the conference please visit: https://events.benzinga.com/ccc-free-registration.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. is an international pharmaceutical, nutraceutical and cosmeceuticals business
headquartered in Canada. AI Pharmaceuticals Jamaica Limited is a wholly owned subsidiary of Aion that
is in the business of research and development of formulations and products that utilize mushrooms
(functional and ones including psilocybin), fungi, and other natural formulations from medicinal plants in
a legal environment that permits such work and discoveries. AI Pharma is focused upon the
development of medicinal antiviral, antimicrobial, anti-inflammatory, anti-hyperglycemic, and anti-
We look forward to seeing you there.
For further information:
Aion Therapeutic Inc
J Graham Simmons, CEO
416 843 2881
Disclaimer & Reader Advisory
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86226
News Provided by Newsfile via QuoteMedia